Servicio de Oncología Radioterápica, Hospital Universitario La Paz, Madrid, Spain.
Clin Transl Oncol. 2011 Sep;13(9):656-63. doi: 10.1007/s12094-011-0711-0.
A previous study of cancer-related neuropathic pain (NP) found that a 10-fold increase in pregabalin (PGB) use increased patients' satisfaction with treatment. Further research of PGB vs. non-pregabalin (non-PGB) treatment was carried out to assess if the use of more specific NP-targeting drugs, such as PGB, in combined therapy, in patients with cancer-related NP, provides better health outcomes.
Post hoc analysis of PGB- vs. non- PGB-treated patients in a 2-month epidemiological, prospective, multicentre study to assess NP prevalence and management in cancer pain patients visiting radiotherapy oncologic units. Patients undertook the Brief Pain Inventory (BPI), Hospital Anxiety and Depression Scale (HADS), the Medical Outcomes Sleep Scale (MOS-Sleep) and the short form (SF-12) Health Survey.
A total of 273 patients with no previous PGB treatment: 162 were treated with PGB polytherapy and 111 with other treatments. At 8 weeks, satisfaction with treatment was 92.6% (PGB) vs. 78.9% (non-PGB), p=0.0024, and benzodiazepine use 37.8% (non-PGB) vs. 19.8% (PGB), p=0.0009. The decreases in BPI total pain intensity and total interference with activities and in MOS overall sleep problems index were significantly larger in the PGB group.
The addition of more specific NP-targeting drugs to usual treatment, such as PGB, in NP cancer patients provides more satisfaction with treatment and better outcomes in terms of pain intensity, interference with activities and sleep than treatments without specific NP-targeting drugs. Anxiolytic profile of PGB could allow for less use of benzodiazepines.
一项针对癌症相关神经性疼痛（NP）的研究发现，普瑞巴林（PGB）使用量增加 10 倍可提高患者对治疗的满意度。本研究进一步比较了 PGB 与非 PGB 治疗方案，以评估在癌症相关 NP 患者的联合治疗中，使用更具针对性的 NP 靶向药物（如 PGB）是否能带来更好的健康结局。
对一项为期 2 个月的、观察性的、多中心的癌症疼痛患者中 NP 流行情况和管理的前瞻性研究中，接受 PGB 与非 PGB 治疗的患者进行了事后分析。患者接受了简明疼痛量表（BPI）、医院焦虑抑郁量表（HADS）、医疗结局睡眠量表（MOS-Sleep）和健康调查简表（SF-12）的评估。
共有 273 例既往未接受 PGB 治疗的患者：162 例接受 PGB 多疗法治疗，111 例接受其他治疗。8 周时，治疗满意度为 92.6%（PGB）vs. 78.9%（非 PGB），p=0.0024，苯二氮䓬类药物使用率为 37.8%（非 PGB）vs. 19.8%（PGB），p=0.0009。PGB 组患者的 BPI 总疼痛强度、总活动干扰评分和 MOS 总体睡眠问题指数均显著下降。
与不使用 NP 靶向药物的治疗相比，在 NP 癌症患者的常规治疗中加入更具针对性的 NP 靶向药物（如 PGB），可提高治疗满意度，并在疼痛强度、活动干扰和睡眠方面带来更好的结局。PGB 的抗焦虑作用可能会减少苯二氮䓬类药物的使用。
